Prevalence of Apparent Treatment-Resistant Hypertension in Chronic Kidney Disease in Two Large US Health Care Systems.

ABSTRACT:

Background and objectives

More intensive BP goals have been recommended for patients with CKD. We estimated the prevalence of apparent treatment-resistant hypertension among patients with CKD according to the 2017 American College of Cardiology/American Heart Association (ACC/AHA; BP goal <130/80 mm Hg) and 2021 Kidney Disease Improving Global Outcomes (KDIGO; systolic BP <120 mm Hg) guidelines in two US health care systems.

Design, setting, participants, & measurements

We included adults with CKD (an eGFR <60 ml/min per 1.73 m²) and treated hypertension from Kaiser Permanente Southern California and the Veterans Health Administration. Using electronic health records, we identified apparent treatment-resistant hypertension on the basis of (1) BP above the g

SUBMITTER: An J 

PROVIDER: S-EPMC9528269 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature